inoserp

Inoserp is a **polyvalent equine antivenom** composed of highly purified immunoglobulin fragments (F(ab')2), produced by immunizing horses with venoms from medically important snake species representative of the target region[1][5][3]. It is indicated for the treatment of snake envenomation in regions such as sub-Saharan Africa (Inoserp PAN-AFRICA), Europe (Inoserp Europe), and the Middle East/North Africa (Inoserp MENA)[1][2][3]. The antivenom is **lyophilized** and preservative-free, designed for rapid reduction of bleeding, neurotoxic, cytotoxic, and coagulation symptoms following snakebite. Inoserp has demonstrated high safety and efficacy in clinical evaluations, resulting in low rates of amputation and death, and is well tolerated with mostly mild adverse effects[1][5]. It contains a high concentration of F(ab')2 fragments (≥95%), with low total protein content to minimize adverse reactions[1][5]. Mechanistically, its F(ab')2 antibodies **bind and neutralize toxic components of various snake venoms**. The product is manufactured following GMP standards, and clinical data support its rapid improvement of bleeding and neurotoxicity in patients treated for snakebite[1][5][3].

Brand names

InoserpInoserp PAN-AFRICAInoserp EuropeInoserp MENA

Other names

inoserp